TLDR:
- Aevice Health has secured $7 million in seed funding for expansion in Japan, Singapore, and the US
- The startup offers a technology platform for managing chronic respiratory conditions with a smart wearable stethoscope, AeviceMD
Singapore-based Aevice Health has closed a $7 million extended seed funding round, with Cedars-Sinai’s venture unit leading the investment. Other existing investors also participated in the round, including East Ventures, A&D Company, NTUitive, Farquhar Venture Capital, and Silicon Solution Venture. The startup, a spinoff from Nanyang Technological University, provides a technology platform for managing chronic respiratory conditions, featuring a smart wearable stethoscope called AeviceMD. This product is cleared for use in both Singapore and the US.
The funds raised will be used by Aevice Health to further expand its presence in key markets such as Singapore, Japan, and the US, as well as enhance product development. The startup recently joined the Cedars-Sinai Accelerator program to gain insight into the US clinical, regulatory, and healthcare reimbursement systems. Over the past three years, Aevice Health has attracted investment to roll out its wearable respiratory monitor globally, including previous funding rounds from A&D Co., East Ventures, and others. The startup has also started collaboration with Jiva.ai to develop an AI for predicting asthma exacerbations.
